DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fm3mng/pharmapoint) has announced the addition of the "PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023" report to their offering.
Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. The publisher estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.
- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Macular Degeneration Overview
3.2 Macular Edema Overview
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Macular Edema Diagnosis
4.1.2 Macular Degeneration Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
5 Competitive Assessment
5.2 Product Profiles - Major Brands
5.2.1 Lucentis (ranibizumab)
5.2.2 Eylea (aflibercept)
5.2.3 Avastin (bevacizumab)
5.2.4 Macugen (pegaptanib sodium)
5.2.5 Visudyne (verteporfin)
5.2.6 Corticosteroid Implants
6 Unmet Need and Opportunity
6.2 Treatment for Dry AMD
6.3 Longer-Acting Anti-VEGF Drug Therapy
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD
6.5 Less Invasive Drug Formulations
6.6 Awareness and Earlier Patient Diagnosis
6.7 Home Monitoring of AMD Progression
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.1 Abicipar pegol
7.3 Promising Drugs in Early-Stage Development
7.4 Other Drugs in Development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/fm3mng/pharmapoint